Celgene – Cutting-Edge Biotechnology in Oncology
Celgene
Celgene Corporation is an American biotechnology company founded in 1986, when the chemical group Celanese spun it off as an independent company. It was headquartered in Summit, New Jersey. In November 2019 Celgene was acquired by Bristol Myers Squibb for about 74 billion dollars and has since been a BMS subsidiary.
Celgene specialised in haematology, oncology and immunology. Its first major product was Thalomid (thalidomide), approved in the US in 1998 for erythema nodosum leprosum and in 2006 for newly diagnosed multiple myeloma.
Its flagship medicine became Revlimid (lenalidomide), an analogue of thalidomide. It was approved in the US in December 2005 for certain forms of myelodysplastic syndrome and in 2006, in combination with dexamethasone, for multiple myeloma. Pomalyst (pomalidomide) followed later, and Abraxane joined the portfolio with the acquisition of Abraxis BioScience in 2010.
As part of the BMS deal, the immunology drug Otezla (apremilast) was sold to Amgen, while Celgene's haematology medicines, including Revlimid, stayed in the Bristol Myers Squibb portfolio.
Unifarm carries Celgene's Revlimid (lenalidomide) in 10 mg and 25 mg strengths.